GM
Geoff Meacham B of A Securities Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
26
Apogee Therapeutics
APGE
$2.29B
| $38.46 | $95 |
147%
upside
| Buy |
13 Mar ‘25
6 months ago |
|
27
89bio
ETNB
$1.28B
| $8.63 | $25 |
190%
upside
| Buy |
13 Mar ‘25
6 months ago |
|
28
BioMarin Pharmaceuticals
BMRN
$10.7B
| $55.69 | $103 |
85%
upside
| Buy |
20 Feb ‘25
6 months ago |
|
29
BioXcel Therapeutics
BTAI
$52.1M
| $3.58 | $4 |
12%
upside
| Underperform |
7 Jan ‘25
8 months ago |
|
30
Gilead Sciences
GILD
$144B
| $115.76 | $125 |
8%
upside
| Buy |
14 Nov ‘24
9 months ago |
|
31
Vertex Pharmaceuticals
VRTX
$102B
| $396.48 | $575 |
45%
upside
| Buy |
14 Nov ‘24
9 months ago |
|
32
AbbVie
ABBV
$372B
| $210.42 | $210 |
0%
downside
| Neutral |
31 Oct ‘24
10 months ago |
|
33
Eli Lilly
LLY
$673B
| $750.61 | $1,100 |
47%
upside
| Buy |
31 Oct ‘24
10 months ago |
|
34
Lyell Immunopharma
LYEL
$253M
| $13.15 | $20 |
52%
upside
| Underperform |
30 Oct ‘24
10 months ago |
|
35
Tyra Biosciences
TYRA
$630M
| $11.82 | $31 |
162%
upside
| Buy |
18 Oct ‘24
10 months ago |
|
36
Moderna
MRNA
$9.52B
| $24.47 | $110 |
350%
upside
| Neutral |
13 Sep ‘24
1 year ago |
|
37
Amgen
AMGN
$151B
| $279.97 | $330 |
18%
upside
| Neutral |
7 Aug ‘24
1 year ago |
|
38
Merck
MRK
$211B
| $84.61 | $145 |
71%
upside
| Buy |
31 Jul ‘24
1 year ago |
|
|
39
Apogee Therapeutics
APGE
$2.29B
| $38.46 | $80 |
108%
upside
| Buy |
10 May ‘24
1 year ago |
|
40
Johnson & Johnson
JNJ
$426B
| $176.96 | $170 |
4%
downside
| Neutral |
17 Apr ‘24
1 year ago |
|
41
Regeneron Pharmaceuticals
REGN
$59B
| $556.53 | $720 |
29%
upside
| Underperform |
12 Apr ‘24
1 year ago |
|
42
Royalty Pharma
RPRX
$15.8B
| $36.50 | $38 |
4%
upside
| Buy |
12 Apr ‘24
1 year ago |
|
43
Biogen
BIIB
$21.1B
| $143.60 | $260 |
81%
upside
| Neutral |
12 Apr ‘24
1 year ago |
|
44
Janux Therapeutics
JANX
$1.43B
| $23.78 | $48 |
102%
upside
| Buy |
13 Mar ‘24
1 year ago |
|
45
Bristol-Myers Squibb
BMY
$96.1B
| $47.23 | $60 |
27%
upside
| Neutral |
3 Jan ‘24
1 year ago |
|
|
46
Gilead Sciences
GILD
$144B
| $115.76 | $95 |
18%
downside
| Buy |
8 Sep ‘23
2 years ago |
|
47
CureVac
CVAC
$1.21B
| $5.38 | $8 |
49%
upside
| Underperform |
21 Aug ‘23
2 years ago |
|
48
Rani Therapeutics
RANI
$23.9M
| $0.4994 | $17 |
3,304%
upside
| Buy |
21 Aug ‘23
2 years ago |
|
49
Pfizer
PFE
$140B
| $24.71 | $45 |
82%
upside
| Neutral |
21 Apr ‘23
2 years ago |
|
|
LENZ
50
LENZ Therapeutics
LENZ
$1.14B
| $39.89 | $14 |
65%
downside
| Underperform |
23 Feb ‘23
2 years ago |
|